Atrogi Doses First Subjects in Phase 1 Trial of Muscle-Boosting ATR-258
Stockholm, Sweden – Atrogi AB, a Swedish biotech company focused on metabolic and muscle health, has begun dosing participants in a human trial evaluating its lead candidate, ATR-258. The Phase 1 trial, announced today, March 18, 2026, is designed to assess the physiological effects of the oral therapy on muscle tissue, offering a potential new approach to conditions involving muscle wasting and metabolic dysfunction.
ATR-258 is designed to mimic the effects of exercise, aiming to drive fat loss, increase muscle mass, and improve overall metabolism. This first-in-class oral therapy targets a specific pathway – the GRK-targeted β2-adrenergic signaling pathway – offering a novel mechanism for addressing metabolic disorders. The trial’s initiation follows landmark research published in Cell in June 2025, which validated Atrogi’s approach to unlocking the therapeutic potential of muscle-targeted β2-agonists while minimizing cardiovascular side effects, a common concern with earlier generations of these drugs.
Understanding the Target: β2-Adrenergic Signaling and Muscle Health
The β2-adrenergic receptor plays a crucial role in regulating muscle function and metabolism. Activating this receptor can stimulate muscle growth and fat breakdown, similar to the effects of exercise. However, traditional β2-agonists have been limited by cardiovascular side effects. Atrogi’s technology focuses on selectively targeting this receptor, aiming to harness its benefits without the unwanted consequences. This selectivity is achieved through GRK (G protein-coupled receptor kinase) targeting, a process that modulates the signaling pathway. Atrogi’s pipeline is built on this concept, exploring applications for conditions like type 2 diabetes, obesity, and muscle-wasting diseases.
Trial Design and Participant Profile
The current trial is an 8-week, investigator-initiated interventional study being led by Associate Professor Morten Hostrup at the University of Copenhagen, a leading authority on β2-adrenergic receptor signaling in skeletal muscle. The study will involve overweight male volunteers who will receive daily oral doses of ATR-258. Researchers will examine biased β2-adrenergic receptor (β2-AR) signaling in human skeletal muscle, measuring the extent to which ATR-258 replicates the physiological effects of exercise. The focus is on understanding how the drug impacts muscle growth, function, and overall metabolic health.
According to Professor Hostrup, the trial will allow for a “rigorous interrogation” of the signaling pathways involved in muscle function. By combining detailed muscle physiological measurements with advanced molecular analysis, the researchers hope to gain a deeper understanding of how biased β2-adrenergic signaling regulates muscle growth and function. This knowledge could potentially lead to new treatments for conditions characterized by muscle wasting, such as immobilization, aging, and weight loss.
Previous Safety Data and Tolerability
The initiation of this trial builds on positive safety data from a previous Phase 1 study. Data from a 69-subject Phase 1 trial, detailed in the recent press release, demonstrated that ATR-258 was safe and well-tolerated in both healthy volunteers and individuals with type 2 diabetes. This earlier trial provides a foundation for the current investigation into the drug’s muscle physiological effects.
Beyond Muscle Wasting: Potential Applications
While the current trial focuses on muscle physiology, the potential applications of ATR-258 extend beyond muscle-wasting conditions. The drug’s ability to mimic the effects of exercise suggests it could be beneficial in managing metabolic disorders like obesity and type 2 diabetes. The growing global prevalence of type 2 diabetes – currently affecting over half a billion people worldwide – underscores the need for new therapeutic approaches. Atrogi’s website highlights the potential of its technology to address this significant public health challenge.
What’s Next for ATR-258?
Paul Little, CEO of Atrogi, emphasized that initiating this study and dosing the first subjects represents a significant milestone for the company. With established safety and a validated mechanism of action, the data generated from this trial will be crucial in guiding the further development of ATR-258. The company anticipates sharing the results of the study later this year. Following this Phase 1 trial, Atrogi plans to leverage the muscle physiology data to support the drug’s development across a broader range of metabolic and muscle-wasting conditions. Further clinical trials will likely be needed to confirm these findings and assess the drug’s efficacy in larger patient populations. The company will likewise be closely monitoring the ongoing research in the field of β2-adrenergic signaling to refine its approach and maximize the therapeutic potential of ATR-258.
The broader field of GPCR pathway-signalling modulation is also under intense scrutiny, with researchers continually seeking ways to target these pathways for therapeutic benefit. The success of Atrogi’s approach could pave the way for the development of other novel therapies targeting similar pathways, offering new hope for individuals with metabolic and muscle-related disorders. PMLiVE’s coverage of the trial highlights the potential for ATR-258 to become a significant advancement in the treatment of these conditions.